Skip to main content

Else Nutrition targets FDA approval as it eyes news markets for its plant-based infant nutrition

--News Direct--

Else Nutrition CEO Hamutal Cohen Yitzhak tells Proactive's Stephen Gunnion that a number of catalyst lie ahead for the company this year, including the launch of its 'ready-to-drink' infant nutrition in the US, its entry to the UK market as a starting point for Europe and Australia as a gateway to China.

Importantly, she said the company remains on track to begin its infant growth clinical study for the FDA and European permits. Receiving FDA approval is a very high priority for Else Nutrition, as it believes that becoming the first non-dairy and non-soy FDA-approved infant formula will be transformational. Yitzhak also commented on Else's first-quarter results, which showed an 80% year-over-year increase in revenue to $2.9 million.

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/else-nutrition-targets-fda-approval-as-it-eyes-news-markets-for-its-plant-based-infant-nutrition-799007741

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.